SSR Mining Announces Restart of Operations at Seabee
DENVER — SSR Mining Inc. (Nasdaq/TSX: SSRM) ('SSR Mining' or the 'Company') announces that operations at Seabee were restarted in the evening of June 13, 2025. Operations had been suspended for approximately two weeks due to temporary power interruptions caused by forest fires to the north of the mine. Power supply has been fully restored and there was no damage to the site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Acromegaly Treatment Market to Reach USD 2.51 Billion by 2030 driven by Expanded Oral Therapies and Rising Diagnosis Rates
"Acromegaly Treatment Market" Mordor Intelligence has published a new report on the acromegaly treatment market offering a comprehensive analysis of trends, growth drivers, and future projections. Introduction According to a 2025 report on Acromegaly Treatment Market by Mordor Intelligence the market is projected to grow from USD 1.75 billion in 2025 to USD 2.51 billion by 2030, at a compound annual growth rate (CAGR) of 7.4%. Acromegaly is a rare hormonal disorder caused by excessive secretion of growth hormone (GH), typically due to a benign tumor on the pituitary gland. The condition leads to abnormal growth of bones and tissues, often resulting in physical deformities, metabolic complications, and cardiovascular issues if left untreated. The acromegaly treatment market has been growing steadily as awareness increases, diagnostic capabilities improve, and newer therapeutic approaches emerge. Key Trends The acromegaly treatment market is witnessing several notable trends shaping its trajectory: • Shift toward long-acting and oral formulations Manufacturers are introducing extended-release depot injections and novel oral therapies. The FDA's 2020 approval of MYCAPSSA (oral octreotide) has opened doors for at home administration. Growth hormone receptor antagonists like pegvisomant and emerging oral agents (e.g. paltusotine) are attracting attention due to simplified regimens and improved patient adherence. • Improved diagnosis and earlier detection protocols Updated guidelines and enhanced disease awareness globally are enabling earlier identification of GH secreting pituitary adenomas. This leads to timely treatment and is expected to boost market growth by approximately 1.9% CAGR in North America and Europe. • Geographic growth acceleration in Asia-Pacific Asia-Pacific is projected to grow at an 8.2% CAGR through 2030, outpacing regional averages. Increased healthcare investments, growing specialist density, and expanding private insurance coverage especially in China, Japan, and South Korea are key growth drivers. Market Segmentation The acromegaly treatment market is segmented by product type and distribution channel: By Product Type Somatostatin analogs: Represent the largest segment in 2024 with a 55% market share. These are widely endorsed as first line therapy due to their strong efficacy. Depot formulations (e.g., lanreotide, octreotide) are well established, and clinical use continues to expand. Growth hormone receptor antagonists (GHRAs): Although their market share is smaller currently, this segment is growing faster, projected at roughly 9.5% CAGR to 2030. Products like pegvisomant and oral agents such as paltusotine show strong biochemical control in trials. Dopamine agonists: Utilize a different mechanism and typically serve as adjunct therapy or in mild acromegaly cases. This segment remains niche. Other product types: Includes emerging therapies such as antisense RNA, GHRH receptor blockers, and novel injectables. These are mostly in early pipeline stages and target refractory cases. By Distribution Channel Hospital pharmacies: Captured approximately 61% of the market in 2024, largely due to the need for specialist oversight during initiation, dose titration, and imaging follow up of injectable therapies. Retail pharmacies: Although smaller, this traditional outpatient channel remains important especially for refill prescriptions after stabilization under clinical supervision. Online pharmacies: The fastest growing segment with an estimated CAGR of 13.6% through 2030. Growth is driven by the rise of oral treatments (e.g., MYCAPSSA) and broader telemedicine and digital dispensing adoption. By Geography North America: Largest regional market with 43% share in 2024. Dominance is supported by high diagnosis rates, new treatment approvals, and payer support (e.g., Medicare Part D cap) Europe: A significant market with stable growth, supported by predictable EMA approval processes and health technology assessments. Asia‑Pacific: Fastest growing region at around 8.2% CAGR. Growth is fueled by rising specialist availability and public/private insurance expansions in countries like China, India, Japan, and South Korea. Middle East & Africa: Emerging market with limited current data but increasing interest in rare disease treatment access. South America: Gradual development, with pockets of access in Brazil and Argentina driven by improved regulatory frameworks. Key Players The global acromegaly treatment market shows a moderately concentrated competitive landscape, led by both big pharmaceutical companies and innovative biotechs. Novartis A leading global pharmaceutical company, Novartis stands out in this market thanks to its established portfolio of somatostatin analogs. The report highlights Novartis among the top five companies, reflecting its significant influence and market share in acromegaly treatment. Ipsen Another major specialist in endocrine disorders, Ipsen's Somatuline (lanreotide) program is a consistently high revenue performer. The firm is frequently recognized alongside Novartis and Pfizer as a top acromegaly treatment provider. Pfizer Pfizer is repeatedly listed among the top tier players in acromegaly treatment, indicating its meaningful presence likely via advanced depot therapies and a global distribution network. Recordati S.p.A. Positioned within the core competitive ensemble, Recordati is noted for its focus on rare endocrine diseases and strategic acquisitions in the field, reinforcing its role in the acromegaly treatment space. Amryt Pharma plc Identified as one of the major players, Amryt contributes to the market through innovative therapies and participation in developing newer treatment modalities for acromegaly Conclusion The acromegaly treatment market is on a healthy upward path, largely fueled by therapeutic innovations and improved diagnosis. Transition to long-acting depots and oral therapies offers convenience and enhanced adherence, while robust pipelines in GH receptor antagonists signal sustained growth. Geographically, North America with a 43% market share in 2024 continues to dominate, underpinned by policy measures like the U.S. Medicare Part D cap and proactive health technology assessments. Meanwhile, Asia Pacific is emerging as the fastest growing region, presenting new market opportunities. Looking forward, early diagnosis, increasing access through digital pharmacies, and expanding oral treatment options suggest continued market expansion. With a projected valuation of USD 2.51 billion by 2030 and a steady 7.4% CAGR, the acromegaly treatment landscape will continue to evolve rooted in patient centric delivery modes and clinical advancements. For More Insights: Industry Related Reports: Somatostatin Analogs Market: The Somatostatin Analogs Market Report is segmented by Type (Octreotide, Lanreotide, Pasireotide, and Other Types), by Application (Acromegaly, Neuroendocrine Tumors (NETs), and Other Applications), and by Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecasts are provided in terms of value (USD) for all the above segments. Neuroendocrine Tumor Treatment Market : The Neuroendocrine Tumor Treatment Market Report is segmented by Products (Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, and Others), by Indication (Lungs, Pancreas, Gastrointestinal, and Others), by End User (Hospitals, Clinics, and Others), and by Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides five years of historical data along with five years' market forecasts. Get More Insights: Norway Pharmaceutical Market: The Norway Pharmaceutical Market Report is segmented by ATC/Therapeutic Class (Cardiovascular System, Dermatologicals, Genito Urinary System, Anti-infective for Systemic Use, Antineoplastic and Immunomodulating Agents, Musculoskeletal System, Nervous System, Respiratory System, and Others), by Drug Type (Branded and Generic), and by Prescription Type (Prescription Drugs (Rx) and Over the Counter (OTC) Drugs). About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For any inquiries or to access the full report, please contact: media@
Globe and Mail
an hour ago
- Globe and Mail
Support for solar energy and offshore wind falls among Democrats and independents, AP-NORC poll says
Americans' support for green energy tax credits and renewable energies like wind and solar power has decreased in recent years, according to a new poll, driven by a softening in support from Democrats and independents. The poll from The Associated Press-NORC Center for Public Affairs Research finds that U.S. adults' support for tax credits for electric vehicles and solar panels has weakened, as well as their enthusiasm for offshore wind farm expansion. While Democrats remain the strongest supporters of these initiatives, the poll reveals signs of growing cynicism within their ranks. The poll results coincide with sweeping changes President Donald Trump's Republican administration is making to regulations related to energy and climate change, including slashing the federal workforce in these departments. And although Democrats and independents have weakened their support for some green energy initiatives, there has not been an increase in support for Trump's energy policies. The poll found only about 4 in 10 U.S. adults — including only 1 in 10 Democrats and about 2 in 10 independents, along with three-quarters of Republicans — approve of the way Trump is handling climate change, which largely tracks with his overall approval rating. Democrats and independents drive decline in support for renewable energy credits About 6 in 10 Democrats, 58%, favor tax credits for purchasing an electric vehicle, down from about 7 in 10 in 2022. Among independents, support declined from 49% in 2022 to 28%. Only one-quarter of Republicans supported this policy in 2022, and that hasn't changed measurably. 'As far as the pollution goes ... the vehicles nowadays put out very little emissions to the air,' said JD Johnson, a 62-year-old Democrat from Meadowview, Virginia, who somewhat opposes tax credits to purchase an electric vehicle. That's partly because he sees the electric vehicle manufacturing process as energy intensive and believes gasoline-powered vehicles have made improvements with the pollutants they emit. The decline in favoring solar panel tax credits was across the board rather than being concentrated among Democrats. 'For solar panels, in all honesty, I don't think they're that efficient yet,' said Glenn Savage, 78, a left-leaning independent from Rock Hill, South Carolina. 'I'd rather see them pour money into research and try to get the solar panels more efficient before they start giving tax breaks to the public. I may be wrong on that, but that's just my thought.' Scientists say transitioning to renewable energies and ditching fossil fuels that release planet-warming emissions are essential to protect the planet. Billions of dollars in project grants for clean technologies awarded during President Joe Biden's Democratic administration have been canceled by the Trump administration, and the offshore wind sector has been stunted by Trump's executive order that paused approvals, permits and loans for wind energy projects. Fewer than half of U.S. adults, 44%, now say that offshore wind farms should be expanded in the U.S., down from 59% in 2022. About half favor expanding solar panel farms, while about two-thirds were in support in 2022. When people are concerned about the economy and their personal finances, environmental issues are sometimes prioritized less, said Talbot Andrews, an assistant professor in the department of government at Cornell University who was not involved in the poll. 'I think it makes people anxious to think about increased taxes or increased spending on environmental issues when the cost of eggs are going through the roof,' Andrews said. Low support for Trump's efforts to expand offshore drilling and coal mining Trump has championed the expansion of offshore oil drilling, as well as domestic coal production. Despite a decline in support for expanded renewable energies, the new poll shows that only about one-third of U.S. adults think offshore drilling for oil and natural gas should be expanded in the U.S., and only about one-quarter say this about coal mining. In both cases, Republicans are much more likely than Democrats to support expanding these energy sources. Trump has sought to open up national monuments for oil drilling, but more U.S. adults oppose than support auctioning off more public space for oil drilling. Only about one-quarter of U.S. adults favor this, while 4 in 10 are opposed. Republicans are much more likely than independents or Democrats to be in support. Bipartisan support for consumer rebates and home appliance ratings The Energy Star program that certifies appliances, such as dishwashers and refrigerators, as energy efficient recently appeared in headlines when the EPA made plans to scrap the program. The blue and white logo is well recognized, and experts say the program has long had bipartisan support until recently. The poll found three-quarters of Democrats support providing consumer rebates for efficient home appliances, compared with 6 in 10 Republicans. Patrick Buck, 54, from Chicago, describes himself as a liberal Republican and is a fan of the consumer rebates for energy-efficient appliances. 'It seems to work in terms of transforming what people have in their houses, because a lot of people have a lot of old appliances and just can't afford new ones,' he said. Safe air, water, meat and produce The poll found only about 2 in 10 U.S. adults are 'extremely' or 'very' confident in the federal government's ability to ensure the safety of their drinking water, the air they breathe and the meat, poultry, fruits and vegetables they buy in grocery stores. About 4 in 10 U.S. adults are 'somewhat' confident in the federal government's ability to ensure the safety of each of these, and about 4 in 10 are 'not very' or 'not at all' confident. The Trump administration has announced plans to roll back rules and policies related to limiting pollution and greenhouse gas emissions, such as rules that limit pollution from power plants and blocking California's efforts to phase out cars that run on gas. The federal government has also cut staff at the Food and Drug Administration, the federal agency tasked with protecting public health and ensuring food supply safety. ___ The AP-NORC poll of 1,158 adults was conducted June 5-9, using a sample drawn from NORC's probability-based AmeriSpeak Panel, which is designed to be representative of the U.S. population. The margin of sampling error for adults overall is plus or minus 4 percentage points. ___ The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. The AP is solely responsible for all content. Find the AP's standards for working with philanthropies, a list of supporters and funded coverage areas at
National Post
2 hours ago
- National Post
HSBC Experts Share Strategies for Managing Art as an Alternative Asset Class
Article content Sorry, your browser doesn't support embedded videos. Article content HSBC Private Banking Hosts 'Artfully Investing: An Art Market Update and Private Planning Discussion' at the renowned Berry Campbell Gallery Article content Article content NEW YORK — HSBC Private Banking's Women's Committee welcomed an exclusive group of clients and industry leaders for Artfully Investing, a discussion exploring the intersection of art, wealth planning, and legacy building. Hosted in the vibrant setting of Berry Campbell Gallery in Chelsea, Manhattan, the event brought together a distinguished panel of experts to discuss the evolving art market, collection strategy, and critical planning issues for sophisticated collectors. Article content Moderated by Carly Doshi, Head of Wealth Planning and Advisory at HSBC, the panel featured insights from Christine Berry, Co-Founder of the Berry Campbell Gallery; Gabrielle Segal, Founder of GS Art Concierge; and Ron Fiamma, President and Co-Founder of Treadwell. Together, the panel addressed topics ranging from art valuation and estate planning to insurance and emotional investment in collecting. Article content 'We want collectors, both new and experienced, to think through how their collections fit into their broader financial and estate-planning strategy,' said Doshi. 'Our aim is to bring together clients, colleagues, and friends for meaningful conversations about enhancing personal wealth and legacy.' Article content Against the backdrop of a new solo exhibition by surrealist painter Lucia Wilcox, the conversation emphasized not just financial best practices, but also the social and emotional dimensions of collecting. The gallery, co-founded by Christine Berry and Martha Campbell, has made a name for itself by championing historically overlooked artists, particularly women working in postwar and contemporary movements. Article content Panel Highlights: Article content Carly Doshi underscored the importance of integrating art holdings into a holistic wealth plan—including estate tax strategy, insurance, and collaboration with financial professionals. Gabrielle Segal encouraged collectors to maintain 'financial hygiene,' stressing the importance of regular appraisals, insurance updates, and understanding motivations behind collecting. Ron Fiamma addressed emerging risks and trends, including climate-related threats to physical assets and the growing use of art as collateral in sophisticated planning strategies. Christine Berry shared the gallery's mission to rewrite art history by spotlighting underrepresented voices, while also educating collectors on tax implications and the role of professional appraisers. Article content Berry Campbell Gallery, a woman-founded institution that has expanded since its inception in 2013, hosted the event. With a growing reputation for discovering and re-contextualizing overlooked artists, the gallery continues to make waves in the international art world. Article content HSBC's Artfully Investing series reflects the bank's commitment to empowering clients with the knowledge and tools to protect and grow their collections—not only as valuable assets but as lasting legacies. Article content About HSBC Article content , is headquartered in London. HSBC serves customers worldwide from offices in 58 countries and territories. With assets of US$3,054bn at 31 March 2025, HSBC is one of the world's largest banking and financial services organizations. Article content HSBC Bank USA, National Association (HSBC Bank USA, N.A.) Article content serves customers through International Wealth and Premier Banking (IWPB) and Corporate and Institutional Banking (CIB). Deposit products are offered by HSBC Bank USA, N.A., Member FDIC. It operates Wealth Centers in: California; Washington, D.C.; Florida; New Jersey; New York; Virginia; and Washington. HSBC Bank USA, N.A. is the principal subsidiary of HSBC USA Inc., a wholly-owned subsidiary of HSBC North America Holdings Inc. HSBC Innovation Banking in the U.S. is a business division with services provided in the United States by HSBC Bank USA, N.A. Article content Article content
